<DOC>
	<DOCNO>NCT02799758</DOCNO>
	<brief_summary>The purpose study demonstrate superior efficacy NK-104-CR 8 mg daily compare Livalo速 IR 4 mg daily fast serum low-density lipoprotein cholesterol ( LDL-C ) reduction evaluate comparative safety NK-104-CR 8 mg daily Livalo速 IR 4 mg daily long-term treatment</brief_summary>
	<brief_title>Efficacy &amp; Long-term Safety Comparison Study NK-104-CR &amp; Livalo速 IR With Primary Hyperlipidemia Mixed Dyslipidemia</brief_title>
	<detailed_description />
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Pitavastatin</mesh_term>
	<criteria>Male female patient primary hyperlipidemia mixed dyslipidemia Patients lipidlowering therapy indicate accord NCEP ATPIII Patients na誰ve statin able safely discontinue use lipidlowering agent 4 week randomization throughout study participation Homozygous familial hypercholesterolemia ; Any condition may cause secondary dyslipidemia . Newly diagnose poorly control diabetes mellitus define HbA1c &gt; 9 %</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>